Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cell proliferation markers in acute leukemia

F Lacombe1, F Belloc

  • 1Laboratoire d'Hématologie, CHR Bordeaux, Hôspital Haut-Lévèque, Pessac, France.

Leukemia & Lymphoma
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Harmonemia: a universal strategy for flow cytometry immunophenotyping-A European LeukemiaNet WP10 study.

Leukemia·2016
Same author

PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor.

Cell death & disease·2013
Same author

Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10.

Leukemia·2011
Same author

Coherent femtosecond pulse shaping for the optimization of a non-linear micro-endoscope.

Optics express·2009
Same author

The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells.

Leukemia·2009
Same author

Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study.

Leukemia·2008
Same journal

Glofitamab for the treatment of relapsed/refractory hairy cell leukemia: a case report.

Leukemia & lymphoma·2026
Same journal

Pre- and post-transplant serum albumin levels and outcomes after allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia.

Leukemia & lymphoma·2026
Same journal

Leukemia mortality analysis in the pediatric population in São Paulo state, Brazil, 2000-2019.

Leukemia & lymphoma·2026
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
See all related articles

Cell proliferation in acute myeloid leukemia (AML) impacts therapy response. This study reviews markers for cell cycle and proliferation to better understand leukemic cell growth.

Area of Science:

  • Hematology
  • Oncology
  • Cell Biology

Background:

  • Leukemic blast cell proliferation is critical in acute myeloid leukemia (AML) treatment outcomes.
  • Numerous studies have investigated leukemic cell growth using diverse methodologies.
  • A variety of proliferation markers exist, often showing strong correlations.

Purpose of the Study:

  • To review and discuss markers that assess cell cycle parameters.
  • To examine markers specifically related to cell proliferation in AML.
  • To consolidate understanding of key indicators for leukemic cell growth.

Main Methods:

  • Literature review of studies on acute myeloid leukemia cell proliferation.
  • Analysis of various proliferation markers used in hematologic oncology research.

Related Experiment Videos

  • Categorization of markers based on their assessment of cell cycle or direct proliferation.

    • Main Results:

    • Cell cycle parameters and proliferation markers are closely correlated in AML studies.
    • Specific markers offer distinct insights into leukemic cell kinetics.
    • Understanding these markers is essential for interpreting therapeutic responses.

    Conclusions:

    • A comprehensive understanding of cell cycle and proliferation markers is vital for AML research.
    • Selecting appropriate markers can refine the assessment of leukemic blast cell behavior.
    • Further research may benefit from a focused approach on specific marker categories.